Core Viewpoint - Eli Lilly collaborates with NVIDIA to build a powerful supercomputer and AI factory aimed at accelerating drug development in the pharmaceutical industry, expected to launch in January next year [2][4]. Group 1: AI in Drug Development - The pharmaceutical industry's efforts to utilize AI for accelerating drug approvals are still in the early stages, with no AI-designed drugs yet on the market, but an increase in AI-discovered drugs entering clinical trials [4]. - Eli Lilly's Chief AI Officer, Thomas Fuchs, describes the supercomputer as a novel scientific instrument, akin to a giant microscope for biologists [5]. - The supercomputer will enable scientists to train AI models through millions of experiments, significantly expanding the scope and complexity of drug discovery [6]. Group 2: Precision Medicine - The new AI tools are not solely focused on drug discovery but represent a significant opportunity to discover new molecules that humans may not identify [7]. - Eli Lilly emphasizes that new scientific AI agents can support researchers and advanced medical imaging can help in observing disease progression and developing biomarkers for precision treatment [9][10]. - NVIDIA's healthcare VP, Kimberly Powell, states that achieving the promise of precision medicine requires AI infrastructure, which is being built, with Eli Lilly serving as a prime example [11]. Group 3: Open Platform for Data Sharing - Multiple AI models will be available on the Lilly TuneLab platform, launched by Eli Lilly in September last year, which allows biotech companies to access drug discovery models trained on proprietary research data valued at $1 billion [13]. - The platform aims to broaden industry access to drug discovery tools, with Powell noting the significance of assisting startups that might otherwise take years to reach similar stages [14]. - In exchange for access to the platform, biotech companies are expected to contribute some of their research and data to help train the AI models [15].

Core Viewpoint - Eli Lilly collaborates with NVIDIA to build a powerful supercomputer and AI factory aimed at accelerating drug development, expected to launch in January next year [1][3] Group 1: Supercomputer and AI Factory - The supercomputer will consist of over 1,000 NVIDIA Blackwell Ultra GPUs connected through a unified high-speed network [3] - The system is designed to power an AI factory specifically for large-scale development, training, and deployment of AI models in drug discovery [3] - Eli Lilly's Chief Information and Digital Officer, Diogo Rau, indicated that significant returns from these new tools may not be realized until 2030 [3][6] Group 2: AI in Drug Discovery - Currently, no drugs designed using AI have been approved, but there is an increase in the number of AI-discovered drugs entering clinical trials [5] - Eli Lilly's Chief AI Officer, Thomas Fuchs, described the supercomputer as a novel scientific instrument that will allow scientists to train AI models through millions of experiments [6] - Rau emphasized that while drug discovery is a major focus, the new tools will also support other research areas [7] Group 3: Precision Medicine - Eli Lilly plans to use the supercomputer to shorten drug development cycles and enhance treatment efficacy [8] - Precision medicine aims to customize disease prevention and treatment based on individual genetic, environmental, and lifestyle differences [9] - NVIDIA's healthcare VP, Kimberly Powell, stated that AI infrastructure is essential for realizing the promise of precision medicine [10] Group 4: Data Sharing and Collaboration - Multiple AI models will be available on the Lilly TuneLab platform, which was launched last September, allowing biotech companies access to Eli Lilly's drug discovery models valued at $1 billion [12] - The platform aims to broaden industry access to drug discovery tools, with biotech companies contributing their research and data to help train AI models [13]